Addition of cetuximab to chemotherapy shortens OS in advanced colorectal cancer subset
ERBITUX (cetuximab)
cetuximab
JCI Insight - First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients
ERBITUX (cetuximab) for Head and Neck Cancer and Colorectal Cancer - Cancer Therapy Advisor
Cancers | Free Full-Text | Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G | HTML
Locoregional Head & Neck Cancer | HCP | ERBITUX (cetuximab)
PPT - Management of Metastatic Colorectal Cancer: Focus on Targeted Therapy PowerPoint Presentation - ID:437568
The challenge of managing a cetuximab rash | MDedge Hematology and Oncology
Regimen Reference Order
PRSS contributes to cetuximab resistance in colorectal cancer | Science Advances
Quick Reference Guide - MRSA Topical Eradication
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members | Oncogene
Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study - European Journal of Cancer
PDF) Alternate Dosing of Cetuximab for Patients With Metastatic Colorectal Cancer
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck | NEJM
Cetuximab in the management of nasopharyngeal carcinoma – a narrative review | The Journal of Laryngology & Otology | Cambridge Core
REACH treatment schedule: Cetuximab (Erbitux®) is given at a loading... | Download Scientific Diagram
Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience - International Journal of Radiation Oncology, Biology, Physics
![Consistent administration of cetuximab is associated with favorable outcomes in recurrent/metastatic head and neck squamous cell carcinoma in an endemic carcinogen exposure area: a retrospective observational study [PeerJ]](https://dfzljdn9uc3pi.cloudfront.net/2020/9862/1/fig-1-full.png "Consistent administration of cetuximab is associated with favorable outcomes in recurrent/metastatic head and neck squamous cell carcinoma in an endemic carcinogen exposure area: a retrospective observational study [PeerJ]")
Consistent administration of cetuximab is associated with favorable outcomes in recurrent/metastatic head and neck squamous cell carcinoma in an endemic carcinogen exposure area: a retrospective observational study [PeerJ]
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study - Annals of Oncology
Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer | Research To Practice
Regimen Reference Order – H&N – cetuximab + fluorouracil + CARBOplatin
Overview of selected cetuximab q2w dosing studies in which KRAS... | Download Table
